<!DOCTYPE html>
<html lang="es">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PERT-Response Pro | Protocolo 2026</title>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/lucide/0.281.0/lucide.min.js"></script>
    <style>
        :root {
            --bg: #0f172a;
            --card: #1e293b;
            --primary: #3b82f6;
            --danger: #ef4444;
            --warning: #f59e0b;
            --success: #10b981;
            --text: #f8fafc;
            --text-dim: #94a3b8;
        }
        body {
            font-family: -apple-system, system-ui, sans-serif;
            background-color: var(--bg);
            color: var(--text);
            margin: 0;
            padding: 15px;
            line-height: 1.5;
        }
        .header {
            text-align: center;
            padding: 20px 0;
            border-bottom: 1px solid #334155;
            margin-bottom: 20px;
        }
        .badge {
            display: inline-block;
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 0.75rem;
            font-weight: bold;
            text-transform: uppercase;
            margin-bottom: 10px;
        }
        .badge-danger { background: rgba(239, 68, 68, 0.2); color: var(--danger); border: 1px solid var(--danger); }
        
        .section-title {
            font-size: 1.1rem;
            color: var(--primary);
            display: flex;
            align-items: center;
            gap: 10px;
            margin: 25px 0 15px 0;
        }
        .card {
            background: var(--card);
            border-radius: 12px;
            padding: 16px;
            margin-bottom: 15px;
            border: 1px solid #334155;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 0.85rem;
            margin-top: 10px;
        }
        th, td {
            text-align: left;
            padding: 10px;
            border-bottom: 1px solid #334155;
        }
        th { color: var(--text-dim); font-weight: 500; }
        .highlight { color: var(--warning); font-weight: bold; }
        .dose-tag {
            background: #334155;
            padding: 2px 6px;
            border-radius: 4px;
            font-family: monospace;
        }
    </style>
</head>
<body>

<div class="header">
    <div class="badge badge-danger">Uso Cl√≠nico Exclusivo</div>
    <h1 style="margin:0; font-size: 1.5rem;">PERT-Response Pro</h1>
    <p style="color: var(--text-dim); margin: 5px 0 0 0; font-size: 0.9rem;">Protocolo de Respuesta R√°pida en TEP</p>
</div>

<div class="section-title">üîç Hallazgos Cr√≠ticos Angio-TC</div>
<div class="card">
    <table>
        <tr>
            <td>Relaci√≥n VD/VI</td>
            <td class="highlight">‚â• 1.0</td>
        </tr>
        <tr>
            <td>Septum IV</td>
            <td>Aplanamiento / Inversi√≥n</td>
        </tr>
        <tr>
            <td>Vena Cava</td>
            <td>Reflujo hacia VCI/Hep√°ticas</td>
        </tr>
        <tr>
            <td>Art. Pulmonar</td>
            <td>Di√°metro > 30 mm (Tronco)</td>
        </tr>
    </table>
</div>

<div class="section-title">‚ö° Protocolo de Reperfusi√≥n</div>
<div class="card">
    <p style="margin-top:0; font-weight:bold; color:var(--danger);">Alteplasa (rtPA):</p>
    <ul style="padding-left: 20px; font-size: 0.85rem; margin: 0;">
        <li><b>Dosis Est√°ndar:</b> 100 mg infusi√≥n en 2 horas.</li>
        <li><b>Dosis "Safe-Dose":</b> 50 mg (Riesgo Intermedio-Alto).</li>
        <li><b>Paro Inminente:</b> 0.6 mg/kg bolo (m√°x 50mg) en 15 min.</li>
    </ul>
</div>

<div class="section-title">üíä Terapia Oral (DOACs)</div>
<div class="card">
    <table>
        <thead>
            <tr>
                <th>F√°rmaco</th>
                <th>Inicio / Carga</th>
                <th>Mantenimiento</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td><b>Apixab√°n</b></td>
                <td class="highlight">10 mg c/12h<br><small>(7 d√≠as)</small></td>
                <td>5 mg c/12h</td>
            </tr>
            <tr>
                <td><b>Rivaroxab√°n</b></td>
                <td class="highlight">15 mg c/12h<br><small>(21 d√≠as)</small></td>
                <td>20 mg c/d√≠a</td>
            </tr>
            <tr>
                <td><b>Dabigatr√°n</b></td>
                <td>Tras 5 d√≠as de Heparina</td>
                <td>150 mg c/12h</td>
            </tr>
            <tr>
                <td><b>Edoxab√°n</b></td>
                <td>Tras 5 d√≠as de Heparina</td>
                <td>60 mg c/d√≠a</td>
            </tr>
        </tbody>
    </table>
    <p style="font-size: 0.75rem; color: var(--warning); margin-top: 15px; border-top: 1px solid #334155; padding-top: 10px;">
        ‚ö†Ô∏è <b>Contraindicaciones:</b> CrCl < 15-30 ml/min, Embarazo, S√≠ndrome Antifosfol√≠pido (SAF) Triple Positivo, Pr√≥tesis Valvular Mec√°nica.
    </p>
</div>

<div class="section-title">üè† Criterios de Manejo Ambulatorio</div>
<div class="card">
    <ul style="padding-left: 20px; font-size: 0.85rem; margin: 0;">
        <li>PESI simplificado = 0</li>
        <li>Estabilidad hemodin√°mica y Saturaci√≥n > 94%</li>
        <li>Ausencia de disfunci√≥n VD en TAC/ECO</li>
        <li>Soporte social y acceso a medicaci√≥n</li>
    </ul>
</div>

<footer style="text-align:center; padding: 20px; color: var(--text-dim); font-size: 0.7rem;">
    Actualizado: Gu√≠as 2024-2026 | No reemplaza el juicio cl√≠nico.
</footer>

</body>
</html>
